WO2013065028A1 - Fixed dose combination containing azithromycin and loteprednol for treatment of ocular infections - Google Patents

Fixed dose combination containing azithromycin and loteprednol for treatment of ocular infections Download PDF

Info

Publication number
WO2013065028A1
WO2013065028A1 PCT/IB2012/056149 IB2012056149W WO2013065028A1 WO 2013065028 A1 WO2013065028 A1 WO 2013065028A1 IB 2012056149 W IB2012056149 W IB 2012056149W WO 2013065028 A1 WO2013065028 A1 WO 2013065028A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
pharmaceutically acceptable
salts
loteprednol
azithromycin
Prior art date
Application number
PCT/IB2012/056149
Other languages
French (fr)
Inventor
Rajesh Kshirsagar
Shivanand Dhanure
Sachin Mundade
Original Assignee
Micro Labs Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micro Labs Limited filed Critical Micro Labs Limited
Publication of WO2013065028A1 publication Critical patent/WO2013065028A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Definitions

  • the present invention relates to a fixed dose combination comprising one or more antibiotics and one or more steroidal anti-inflammatory agents for the treatment of ocular infections.
  • Eye is susceptible to bacterial and parasitic infections arising from both traumatic and non-traumatic related events. Infections are a concern after ocular surgery, and precautions are correspondingly taken to prevent the onset of infection. However, even without the invasive trauma of a surgical procedure, infections in the eyelids, conjunctiva, cornea, and other ocular tissues can occur.
  • the causes of ocular infections generally come from one of two different sources: the eyelids or the sinuses.
  • the most common reasons why the eyes get infected are through surgery, trauma, low immunity, and improper contact care.
  • the treatment of choice for treating ocular infections includes antibiotics and steroidal anti-inflammatory agents.
  • the present inventors have found that a fixed dose combination comprising one or more antibiotics and one or more steroidal anti-inflammatory agents are effective treatment of ocular infections.
  • the present invention is directed to a method of treating ocular infections, comprising administration of a fixed dose combination comprising one or more antibiotics and one or more steroidal anti-inflammatory agents.
  • the present invention provides a fixed dose combination comprising one or more antibiotics and one or more steroidal anti-inflammatory agents for the treatment of ocular infections.
  • the present invention provides a pharmaceutical composition comprising fixed dose combination comprising one or more antibiotics and one or more steroidal anti-inflammatory agents for the treatment of ocular infections.
  • the present invention provides a process for preparation of a pharmaceutical composition comprising a fixed dose combination comprising one or more antibiotics and one or more steroidal anti-inflammatory agents for the treatment of ocular infections.
  • the present invention provides a method of treating an ocular infections, comprising administering to an affected eye of patient a combination of an effective amount of Azithromycin or its pharmaceutically acceptable hydrates or salts thereof and an effective amount of Loteprednol or its pharmaceutically acceptable esters or salts thereof optionally together with pharmaceutically acceptable excipients.
  • the present invention provides a fixed dose combination comprising an effective amount of Azithromycin or its pharmaceutically acceptable hydrates or salts thereof and an effective amount of Loteprednol or its pharmaceutically acceptable esters or salts thereof for the treatment of ocular infections.
  • the present invention provides a pharmaceutical composition comprising fixed dose combination comprising an effective amount of Azithromycin or its pharmaceutically acceptable hydrates or salts thereof and an effective amount of Loteprednol or its pharmaceutically acceptable esters or salts thereof for the treatment of ocular infections.
  • the present invention provides a process for preparation of a pharmaceutical composition
  • a pharmaceutical composition comprising a fixed dose combination comprising an effective amount of Azithromycin or its pharmaceutically acceptable hydrates or salts thereof and an effective amount of Loteprednol or its pharmaceutically acceptable esters or salts thereof for the treatment of ocular infections.
  • the invention includes the combinational use of one or more and antibiotics one or more anti-inflammatory steroids for the treatment of ocular infections. More specifically, the present invention includes a combinational use of an effective amount of Azithromycin or its pharmaceutically acceptable hydrates or salts thereof and an effective amount of Loteprednol or its pharmaceutically acceptable esters or salts thereof for the treatment of ocular infections.
  • Ocular infections refers to infections which are caused by viruses and bacteria entering the eye. While the eyes are constantly exposed to a variety of germs, bacteria, and viruses, sometimes the body's defenses fail and an eye infection can result. Eye infections are most commonly spread by hand-to-eye contact, infections traveling from the sinuses, or through poor eye hygiene (especially contact-lens hygiene). Other causes include complications from eye surgery, eye trauma, immune deficiency, or other eye problems or illness that result in bacteria or viral growth. Systemic overgrowth of the fungus Candida albicans known as Candidiasis can also cause recurrent eye infections and eye pain. Ocular infections can be conjunctivitis, ophthalmic neonatorum, trachoma, corneal ulcers, keratitis, keratoconjunctivitis, endophthalmitis, infectious uveitis and combinations thereof.
  • antibiotics refers to drugs which are produced by micro-organism in nature and isolated from this natural source or synthesized by chemical process which can kill harmful microorganism and cure bacterial infections in human and animals.
  • anti-inflammatory steroids refers to the drugs that block the synthesis of new histamine release by mast cells, inactivate available histamine, inhibit mast cell degranulation, decrease capillary permeability, and inhibit phospholipase A synthesis, which is used in the production of arachidonic acid and thereby prevent inflammation.
  • compositions and formulations described herein comprise a first active agent and a second active agent, wherein the first active agent and the second active agent are formulated into the composition or formulation in a manner that allows ophthalmic and/or topical activity of the agents (e.g., by formulating a composition or formulation described herein as a solution, gel, or the like, comprising a first active agent and a second active agent as solutes within the solution, gel, suspension etc.).
  • compositions and formulations include compositions and formulations wherein a substantial portion, a therapeutically effective portion, most or all of the first and second agents are either dissolved or suspended in the liquid medium (e.g., aqueous medium) based on their solubility in liquid medium.
  • liquid medium e.g., aqueous medium
  • the active components of present invention are present in the form of a fixed dose combination, owing to which the administration is simpler for the patients, since both active compounds are contained in one and the same container.
  • the present invention provides a fixed dose combination of Azithromycin or its pharmaceutically acceptable hydrates or salts thereof and Loteprednol or its pharmaceutically acceptable esters or salts thereof.
  • the antibiotics e.g. Azithromycin or its pharmaceutically acceptable hydrates or salts thereof
  • the antibiotics are present in a composition or formulation described herein in an amount of about 0.1 wt % to about 10 wt %, more preferably 1 wt % to 2 wt %.
  • the anti-inflammatory steroids e.g. Loteprednol or its pharmaceutically acceptable esters or salts
  • the anti-inflammatory steroids are present in a composition or formulation described herein in an amount of about 0.01 wt % to about 5 wt %, more preferably 0.2 wt % to 0.5 wt %.
  • the ophthalmic composition of present invention has a pH from 4.0 to 8.0, preferably from 4.5 to 7.5, more preferably from 5.0 to 7.0.
  • the ophthalmic composition of present invention has an osmolarity from 200 to 400 milliosmoles/liter (mOsm/L), preferably from 250 to 375 mOsm/L, and more preferably from 300 to 360 mOsm/L.
  • mOsm/L milliosmoles/liter
  • compositions, formulations and active pharmaceutical agent described herein are thermally stable at room temperature, at 25° C with relative humidity 40% or at 40 °C with relative humidity not more than 25% for at least 3 months.
  • antibiotics include, but are not limited to, Aminoglycosides such as; Amikacin, Gentamycin, Kanamycin, Neomycin, Netilmicin, Paromomycin, Streptomycin, Tobramycin, Carbapenems such as; Ertapenem, Imipenem, Meropenem, Chloramphenicol, Fluoroquinolones such as; Ciprofloxacin, Gatifloxacin, Gemifloxacin, Grepafloxacin, Levofloxacin, Besifloxacin, Lomefloxacin, Moxifloxacin, Norfloxacin, Ofloxacin, Sparfloxacin, Trovafloxacin, Glycopeptides such as; Vancomycin, Lincosamides such as; Clinda
  • steroidal anti-inflammatory agents include, but are not limited to, Loteprednol etabonate, Prednisolone sulfacetamide, Hydrocortisone , Difluprednate, Fluorometholone acetate, Dexamethasone, Prednisolone phosphate , Rimexolone, 21-acetoxypregnenolone, alclometasone, algestone, amcinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, clobetasol, clobetasone, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort, desonide, desoximetasone, diflorasone, diflucortolone, enoxolone, fluazacort, flucloronide, flumethasone, flunisolid
  • a pharmaceutical composition according to the present invention may include one or more pharmaceutically acceptable buffering agents, preservatives, tonicity- adjusting agents, pH-adjusting agents, chelating agents, viscosity modifiers and wetting agents.
  • buffering agents include, but are not limited to, phosphate buffer, borate buffer, citrate buffer, acetate buffer, carbonate buffer, borate-polyol complexes, boric acid and the like.
  • preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, p- oxybenzoates such as methyl p-oxybenzoate or ethyl p- oxybenzoate, benzyl alcohol, phenethyl alcohol, sorbic acid or its salt, thimerosal, chlorobutanol, other quaternary amines and the like, chlorhexidine gluconate and the like.
  • tonicity-adjusting agents include, but are not limited to, glycerin, mannitol, sodium chloride, xylitol, and the like.
  • alkaline agents examples include, but are not limited to, sodium hydroxide (NaOH), potassium hydroxide (KOH), tromethamine, monoethanolamine, sodium bicarbonate (NaHC0 3 ) and other organic and inorganic bases.
  • acidic agents examples include, but are not limited to, hydrochloric acid, citric acid, tartaric acid, lactic acid and other organic and inorganic acids and the like and mixtures thereof.
  • chelating agents include, but are not limited to EDTA, disodium edetate, sodium citrate, condensed sodium phosphate and the like
  • viscosity modifiers include, but are not limited to, hydroxypropylmethyl cellulose (hypromellose), carboxypropylmethylcellulose, polyvinylpyrrolidone (Povidone), polyethylene glycol, polyvinyl acetate, and combinations thereof.
  • wetting agents include, but are not limited to, cetylpyridinium chloride, tyloxapol, various polysorbates such as Tween ® , polyethoxylated substances and poloxamers.
  • a formulation as shown in table 1 was prepared as follows (a) Accurately weighed quantity of Azithromycin Dihydrate and required quantity of Citric acid anhydrous, Disodium Edetate, Tyloxapol and Glycerin were introduced into suitable container and dissolved in sufficient water for injection and stirred until clear colorless solution obtained. (b) Required quantity of povidone was dissolved in sufficient quantity of water for injection in separate container and stirred till clear solution obtained; this solution was added to solution of step (a) with stirring.
  • step (c) Required quantity of Benzalkonium chloride was dissolved in sufficient quantity of water for injection in separate container and stirred till clear solution obtained; this solution was added to solution of step (a) with stirring to obtain a final solution.
  • step (e) The solution of step (d) was then filtered through 0.22 ⁇ filter.
  • step (f) Accurately weighed quantity of Loteprednol Etabonate (micronized and sterilized) was added to filtered solution of step (e) under laminar air flow unit and homogenized to obtain a final sterile suspension.
  • example 1 was further subjected to stability studies at 40°C/NMT25%RH, and were analyzed at an intervals of 1M, 2M & 3M and at 25°C/40%RH, were analyzed at an intervals of 1M and 3M, the results obtained are presented in Table No. 3.
  • a formulation as shown in table 2 was prepared as follows:
  • step (b) Required quantity of povidone was dissolved in sufficient quantity of water for injection in separate container and stirred till clear solution obtained; this solution was added to solution of step (a) with stirring.
  • step (c) Required quantity of Benzalkonium chloride was dissolved in sufficient quantity of water for injection in separate container and stirred till clear solution obtained; this solution was added to solution of step (a) with stirring to obtain a final solution.
  • step (e) The solution of step (d) was then filtered through 0.22 ⁇ filter.
  • step (f) Accurately weighed quantity of Loteprednol Etabonate (micronized and sterilized) was added to filtered solution of step (e) under laminar air flow unit and homogenized to obtain a final sterile suspension.
  • the formulation of example 2 was further subjected to stability studies at 40°C/NMT25%RH, and were analyzed at an intervals of 1M, 2M & 3M and at 25°C/40%RH, were analyzed at an intervals of 1M and 3M, the results obtained are presented in Table No. 4.
  • NLT Not less than NMT: Not more than RH: Relative Humidity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to use of a fixed dose combination comprising an effective amount of Azithromycin or its pharmaceutically acceptable hydrates or salts thereof and an effective amount of Loteprednol or its pharmaceutically acceptable esters or salts thereof for the treatment of ocular infections. The present invention further relates to a pharmaceutical composition comprising fixed dose combination comprising an effective amount of Azithromycin or its pharmaceutically acceptable hydrates or salts thereof and an effective amount of Loteprednol or its pharmaceutically acceptable esters or salts thereof for the treatment of ocular infections.

Description

FIXED DOSE COMBINATION CONTAINING AZITHROMYCIN AND LOTEPREDNOL FOR TREATMENT OF OCULAR INFECTIONS
FIELD OF THE INVENTION:
The present invention relates to a fixed dose combination comprising one or more antibiotics and one or more steroidal anti-inflammatory agents for the treatment of ocular infections.
BACKGROUND OF THE INVENTION
Eye is susceptible to bacterial and parasitic infections arising from both traumatic and non-traumatic related events. Infections are a concern after ocular surgery, and precautions are correspondingly taken to prevent the onset of infection. However, even without the invasive trauma of a surgical procedure, infections in the eyelids, conjunctiva, cornea, and other ocular tissues can occur.
The causes of ocular infections generally come from one of two different sources: the eyelids or the sinuses. The most common reasons why the eyes get infected are through surgery, trauma, low immunity, and improper contact care.
The treatment of choice for treating ocular infections includes antibiotics and steroidal anti-inflammatory agents.
However literature survey revealed that nobody till date has used fixed dose combination containing antibiotic and steroidal anti-inflammatory agent for the treatment of ocular infections.
The present inventors have found that a fixed dose combination comprising one or more antibiotics and one or more steroidal anti-inflammatory agents are effective treatment of ocular infections.
SUMMARY OF THE INVENTION
The present invention is directed to a method of treating ocular infections, comprising administration of a fixed dose combination comprising one or more antibiotics and one or more steroidal anti-inflammatory agents. In one aspect, the present invention provides a fixed dose combination comprising one or more antibiotics and one or more steroidal anti-inflammatory agents for the treatment of ocular infections.
In yet another aspect, the present invention provides a pharmaceutical composition comprising fixed dose combination comprising one or more antibiotics and one or more steroidal anti-inflammatory agents for the treatment of ocular infections.
In yet another aspect, the present invention provides a process for preparation of a pharmaceutical composition comprising a fixed dose combination comprising one or more antibiotics and one or more steroidal anti-inflammatory agents for the treatment of ocular infections.
In yet another aspect, the present invention provides a method of treating an ocular infections, comprising administering to an affected eye of patient a combination of an effective amount of Azithromycin or its pharmaceutically acceptable hydrates or salts thereof and an effective amount of Loteprednol or its pharmaceutically acceptable esters or salts thereof optionally together with pharmaceutically acceptable excipients.
In yet another aspect, the present invention provides a fixed dose combination comprising an effective amount of Azithromycin or its pharmaceutically acceptable hydrates or salts thereof and an effective amount of Loteprednol or its pharmaceutically acceptable esters or salts thereof for the treatment of ocular infections.
In yet another aspect, the present invention provides a pharmaceutical composition comprising fixed dose combination comprising an effective amount of Azithromycin or its pharmaceutically acceptable hydrates or salts thereof and an effective amount of Loteprednol or its pharmaceutically acceptable esters or salts thereof for the treatment of ocular infections.
In yet another aspect, the present invention provides a process for preparation of a pharmaceutical composition comprising a fixed dose combination comprising an effective amount of Azithromycin or its pharmaceutically acceptable hydrates or salts thereof and an effective amount of Loteprednol or its pharmaceutically acceptable esters or salts thereof for the treatment of ocular infections. DETAILED DESCRIPTION OF INVENTION
The invention includes the combinational use of one or more and antibiotics one or more anti-inflammatory steroids for the treatment of ocular infections. More specifically, the present invention includes a combinational use of an effective amount of Azithromycin or its pharmaceutically acceptable hydrates or salts thereof and an effective amount of Loteprednol or its pharmaceutically acceptable esters or salts thereof for the treatment of ocular infections.
As used herein, the term "ocular infections" refers to infections which are caused by viruses and bacteria entering the eye. While the eyes are constantly exposed to a variety of germs, bacteria, and viruses, sometimes the body's defenses fail and an eye infection can result. Eye infections are most commonly spread by hand-to-eye contact, infections traveling from the sinuses, or through poor eye hygiene (especially contact-lens hygiene). Other causes include complications from eye surgery, eye trauma, immune deficiency, or other eye problems or illness that result in bacteria or viral growth. Systemic overgrowth of the fungus Candida albicans known as Candidiasis can also cause recurrent eye infections and eye pain. Ocular infections can be conjunctivitis, ophthalmic neonatorum, trachoma, corneal ulcers, keratitis, keratoconjunctivitis, endophthalmitis, infectious uveitis and combinations thereof.
As used herein, the term "antibiotics" refers to drugs which are produced by micro-organism in nature and isolated from this natural source or synthesized by chemical process which can kill harmful microorganism and cure bacterial infections in human and animals.
As used herein, the term "anti-inflammatory steroids" refers to the drugs that block the synthesis of new histamine release by mast cells, inactivate available histamine, inhibit mast cell degranulation, decrease capillary permeability, and inhibit phospholipase A synthesis, which is used in the production of arachidonic acid and thereby prevent inflammation.
In one embodiment, the compositions and formulations described herein comprise a first active agent and a second active agent, wherein the first active agent and the second active agent are formulated into the composition or formulation in a manner that allows ophthalmic and/or topical activity of the agents (e.g., by formulating a composition or formulation described herein as a solution, gel, or the like, comprising a first active agent and a second active agent as solutes within the solution, gel, suspension etc.). It is to be understood that such compositions and formulations include compositions and formulations wherein a substantial portion, a therapeutically effective portion, most or all of the first and second agents are either dissolved or suspended in the liquid medium (e.g., aqueous medium) based on their solubility in liquid medium.
In one advantageous embodiment, the active components of present invention are present in the form of a fixed dose combination, owing to which the administration is simpler for the patients, since both active compounds are contained in one and the same container.
In specific embodiment, the present invention provides a fixed dose combination of Azithromycin or its pharmaceutically acceptable hydrates or salts thereof and Loteprednol or its pharmaceutically acceptable esters or salts thereof.
In yet another embodiment, the antibiotics (e.g. Azithromycin or its pharmaceutically acceptable hydrates or salts thereof) are present in a composition or formulation described herein in an amount of about 0.1 wt % to about 10 wt %, more preferably 1 wt % to 2 wt %.
In yet another embodiment, the anti-inflammatory steroids (e.g. Loteprednol or its pharmaceutically acceptable esters or salts) are present in a composition or formulation described herein in an amount of about 0.01 wt % to about 5 wt %, more preferably 0.2 wt % to 0.5 wt %.
In yet other embodiment, the ophthalmic composition of present invention has a pH from 4.0 to 8.0, preferably from 4.5 to 7.5, more preferably from 5.0 to 7.0.
In yet another embodiment, the ophthalmic composition of present invention has an osmolarity from 200 to 400 milliosmoles/liter (mOsm/L), preferably from 250 to 375 mOsm/L, and more preferably from 300 to 360 mOsm/L.
In yet another embodiment, the compositions, formulations and active pharmaceutical agent described herein are thermally stable at room temperature, at 25° C with relative humidity 40% or at 40 °C with relative humidity not more than 25% for at least 3 months. Examples of antibiotics include, but are not limited to, Aminoglycosides such as; Amikacin, Gentamycin, Kanamycin, Neomycin, Netilmicin, Paromomycin, Streptomycin, Tobramycin, Carbapenems such as; Ertapenem, Imipenem, Meropenem, Chloramphenicol, Fluoroquinolones such as; Ciprofloxacin, Gatifloxacin, Gemifloxacin, Grepafloxacin, Levofloxacin, Besifloxacin, Lomefloxacin, Moxifloxacin, Norfloxacin, Ofloxacin, Sparfloxacin, Trovafloxacin, Glycopeptides such as; Vancomycin, Lincosamides such as; Clindamycin, Macrolides/Ketolides such as; Azithromycin, Clarithromycin, Dirithromycin, Erythromycin, Telithromycin, Cephalosporins such as; 1st Generation - Cefadroxil, Cefazolin, Cephalexin, Cephalothin, Cephapirin, Cephradine, 2nd Generation - Cefaclor, Cefamandole, Cefonicid, Cefotetan, Cefoxitin, Cefprozil, Cefuroxime, Loracarbef, 3rd Generation - Cefdinir, Cefditoren, Cefixime, Cefoperazone, Cefotaxime, Cefpodoxime,Ceftazidime, Ceftibuten, Ceftizoxime, Ceftriaxone, 4th Generation - Cefepime, Monobactams such as; Aztreonam, Nitroimidazoles such as; Metronidazole, Oxazolidinones such as Linezolid, Penicillins such as Amoxicillin, Amoxicillin/Clavulanate, Ampicillin, Ampicillin/Sulbactam, Bacampicillin, Carbenicillin, Cloxacillin, Dicloxacillin, Methicillin, Mezlocillin, Nafcillin, Oxacillin, Penicillin G, Penicillin V, Piperacillin, Piperacillin/Tazobactam, Ticarcillin, Ticarcillin/Clavulanate, Streptogramins such as; Quinupristin/Dalfopristin, Tetracyclines such as; Demeclocycline, Doxycycline, Minocycline, Tetracycline or its physiologically acceptable salts thereof, prodrugs thereof, combinations thereof, mixtures thereof and the like.
Examples of steroidal anti-inflammatory agents according to the present invention include, but are not limited to, Loteprednol etabonate, Prednisolone sulfacetamide, Hydrocortisone , Difluprednate, Fluorometholone acetate, Dexamethasone, Prednisolone phosphate , Rimexolone, 21-acetoxypregnenolone, alclometasone, algestone, amcinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, clobetasol, clobetasone, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort, desonide, desoximetasone, diflorasone, diflucortolone, enoxolone, fluazacort, flucloronide, flumethasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluperolone acetate, fluprednidene acetate, fluprednisolone, flurandrenolide, fluticasone propionate, formocortal, halcinonide, halobetasol propionate, halometasone, halopredone acetate, hydrocortarnate, mazipredone, medrysone, meprednisone, methylprednisolone, mometasone furoate, paramethasone, prednicarbate, prednisolone 25-diethylamino-acetate, prednisolone sodium phosphate, prednisone, prednival, prednylidene, tixocortol, triamcinolone, triamcinolone acetonide, triamcinolone benetonide, triamcinolone hexacetonide, prednisone, methylprednisolone, medrysone, triamcinolone or its physiologically acceptable salts thereof, prodrugs thereof, combinations thereof, mixtures thereof and the like.
A pharmaceutical composition according to the present invention may include one or more pharmaceutically acceptable buffering agents, preservatives, tonicity- adjusting agents, pH-adjusting agents, chelating agents, viscosity modifiers and wetting agents.
Examples of buffering agents include, but are not limited to, phosphate buffer, borate buffer, citrate buffer, acetate buffer, carbonate buffer, borate-polyol complexes, boric acid and the like.
Examples of preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, p- oxybenzoates such as methyl p-oxybenzoate or ethyl p- oxybenzoate, benzyl alcohol, phenethyl alcohol, sorbic acid or its salt, thimerosal, chlorobutanol, other quaternary amines and the like, chlorhexidine gluconate and the like.
Examples of tonicity-adjusting agents include, but are not limited to, glycerin, mannitol, sodium chloride, xylitol, and the like.
Examples of the alkaline agents that may be used as pH adjusting agents include, but are not limited to, sodium hydroxide (NaOH), potassium hydroxide (KOH), tromethamine, monoethanolamine, sodium bicarbonate (NaHC03) and other organic and inorganic bases.
Examples of the acidic agents that may be used as pH adjusting agents include, but are not limited to, hydrochloric acid, citric acid, tartaric acid, lactic acid and other organic and inorganic acids and the like and mixtures thereof.
Examples of chelating agents include, but are not limited to EDTA, disodium edetate, sodium citrate, condensed sodium phosphate and the like Examples of viscosity modifiers include, but are not limited to, hydroxypropylmethyl cellulose (hypromellose), carboxypropylmethylcellulose, polyvinylpyrrolidone (Povidone), polyethylene glycol, polyvinyl acetate, and combinations thereof.
Examples of wetting agents include, but are not limited to, cetylpyridinium chloride, tyloxapol, various polysorbates such as Tween®, polyethoxylated substances and poloxamers.
EXAMPLES
The invention will be further illustrated by the following examples, which are intended to be illustrative but not limiting.
Example No. 1
Table No. 1 Ophthalmic Suspension containing Azithromycin Dihydrate Eq. to Azithromycin (1.0 % w/v dissolved) and Loteprednol Etabonate (0.2% w/v suspended)
Figure imgf000008_0001
Manufacturing process:
A formulation as shown in table 1 was prepared as follows (a) Accurately weighed quantity of Azithromycin Dihydrate and required quantity of Citric acid anhydrous, Disodium Edetate, Tyloxapol and Glycerin were introduced into suitable container and dissolved in sufficient water for injection and stirred until clear colorless solution obtained. (b) Required quantity of povidone was dissolved in sufficient quantity of water for injection in separate container and stirred till clear solution obtained; this solution was added to solution of step (a) with stirring.
(c) Required quantity of Benzalkonium chloride was dissolved in sufficient quantity of water for injection in separate container and stirred till clear solution obtained; this solution was added to solution of step (a) with stirring to obtain a final solution.
(d) The pH of final solution obtained as per step (c) was adjusted to 6.0 with required quantity of IN NaOH or 0.1N HCL stock solution and final volume of desired batch size was made up with sufficient quantity of water for injection.
(e) The solution of step (d) was then filtered through 0.22 μ filter. (f) Accurately weighed quantity of Loteprednol Etabonate (micronized and sterilized) was added to filtered solution of step (e) under laminar air flow unit and homogenized to obtain a final sterile suspension.
The formulation of example 1 was further subjected to stability studies at 40°C/NMT25%RH, and were analyzed at an intervals of 1M, 2M & 3M and at 25°C/40%RH, were analyzed at an intervals of 1M and 3M, the results obtained are presented in Table No. 3.
Example No. 2
Table No. 1 Ophthalmic Suspension containing Azithromycin Dihydrate Eq. to Azithromycin (1.0 % w/v dissolved) and Loteprednol Etabonate (0.5% w/v suspended)
Figure imgf000009_0001
4 Disodium Edetate 1.0
5 Citric acid anhydrous 8.0
6 Povidone 6.0
7 Tyloxapol 3.0
8 Glycerin 16.5
9 Sodium Hydroxide/Hydrochloric acid q.s
10 Water for injections q.s to 1 mL
Manufacturing process:
A formulation as shown in table 2 was prepared as follows:
(a) Accurately weighed quantity of Azithromycin Dihydrate and required quantity of Citric acid anhydrous, Disodium Edetate, Tyloxapol and Glycerin were introduced into suitable container and dissolved in sufficient water for injection and stirred until clear colorless solution obtained.
(b) Required quantity of povidone was dissolved in sufficient quantity of water for injection in separate container and stirred till clear solution obtained; this solution was added to solution of step (a) with stirring. (c) Required quantity of Benzalkonium chloride was dissolved in sufficient quantity of water for injection in separate container and stirred till clear solution obtained; this solution was added to solution of step (a) with stirring to obtain a final solution.
(d) The pH of final solution obtained as per step (c) was adjusted to 6.0 with required quantity of IN NaOH or 0.1N HCL stock solution and final volume of desired batch size was made up with sufficient quantity of water for injection.
(e) The solution of step (d) was then filtered through 0.22 μ filter.
(f) Accurately weighed quantity of Loteprednol Etabonate (micronized and sterilized) was added to filtered solution of step (e) under laminar air flow unit and homogenized to obtain a final sterile suspension. The formulation of example 2 was further subjected to stability studies at 40°C/NMT25%RH, and were analyzed at an intervals of 1M, 2M & 3M and at 25°C/40%RH, were analyzed at an intervals of 1M and 3M, the results obtained are presented in Table No. 4. Table No.3: Azithromycin Dihydrate equivalent to Azithromycin base & Loteprednol Etabonate Ophthalmic Suspension (1.0% w/v & 0.2% w/v) finished product analysis data - initial and on stability
Figure imgf000011_0001
M: Month(s) NLT: Not less than NMT: Not more than RH: Relative Humidity Table No. 4: Azithromycin Dihydrate equivalent to Azithromycin base & Loteprednol Etabonate Ophthalmic Suspension (1.0 % w/v & 0.5 % w/v) finished product analysis data - initial and on stability
Figure imgf000012_0001
M: Month(s) NLT: Not less than NMT: Not more than RH: Relative Humidity

Claims

We claim:
1. A stable pharmaceutical composition comprising an effective amount of Azithromycin or its pharmaceutically acceptable hydrates or salts thereof, an effective amount of Loteprednol or its pharmaceutically acceptable esters or salts thereof and pharmaceutically acceptable excipients.
2. The composition of claim 1, wherein the composition comprises from about 0.1 to about 5 % (w/v) of Azithromycin Dihydrate.
3. The composition of claim 1, wherein the composition comprises from about 0.1 to about 1 % (w/v) of Loteprednol Etabonate.
4. The composition of claim 1, wherein said composition is intended for ocular use.
5. The composition of claim 1, wherein the pharmaceutically acceptable excipients are selected from group consisting of buffering agents, preservatives, tonicity- adjusting agents, pH-adjusting agents, chelating agents, viscosity modifiers, wetting agents and combination thereof.
6. The composition of claim 1, wherein the composition has a pH in the range from 5.0 to 7.0.
7. The composition of claim 1, wherein the composition has an Osmolality in the range from about 300 to 360 mOsml /kg.
8. A process for preparation of a pharmaceutical composition comprising a steps of:
(a) dissolving Azithromycin Dihydrate and a pharmaceutically acceptable excipients in water for injection to form a solution; (b) adjusting pH of said solution in the range of 5.0 to 7.0 with pH-adjusting agents; (c) filtering the solution and (d) adding Loteprednol Etabonate to the filtered solution followed by homogenization to obtain a final sterile suspension.
9. A method of treating ocular infections, comprising administering to an affected eye of patient a combination of an effective amount of Azithromycin or its pharmaceutically acceptable hydrates or salts thereof and an effective amount of Loteprednol or its pharmaceutically acceptable esters or salts thereof optionally together with a pharmaceutically acceptable excipients.
10. The method of claim 9, wherein said ocular infections are conjunctivitis, ophthalmic neonatorum, trachoma, corneal ulcers, keratitis, keratoconjunctivitis, endophthalmitis, infectious uveitis and combinations thereof.
PCT/IB2012/056149 2011-11-04 2012-11-05 Fixed dose combination containing azithromycin and loteprednol for treatment of ocular infections WO2013065028A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2666/CHE/2011 2011-11-04
IN2666CH2011 2011-11-04

Publications (1)

Publication Number Publication Date
WO2013065028A1 true WO2013065028A1 (en) 2013-05-10

Family

ID=47326262

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2012/056149 WO2013065028A1 (en) 2011-11-04 2012-11-05 Fixed dose combination containing azithromycin and loteprednol for treatment of ocular infections
PCT/IB2012/056151 WO2013065029A1 (en) 2011-11-04 2012-11-05 Fixed dose combination containing moxifloxacin and prednisolone for treatment of ocular infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/056151 WO2013065029A1 (en) 2011-11-04 2012-11-05 Fixed dose combination containing moxifloxacin and prednisolone for treatment of ocular infections

Country Status (1)

Country Link
WO (2) WO2013065028A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9790232B2 (en) 2013-11-01 2017-10-17 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10688041B2 (en) 2012-05-03 2020-06-23 Kala Pharmaceuticals, Inc. Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus
US10766907B2 (en) 2016-09-08 2020-09-08 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US11219597B2 (en) 2012-05-03 2022-01-11 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11439590B2 (en) 2013-07-22 2022-09-13 Novel Drug Solutions Llc Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US11510916B2 (en) 2013-07-22 2022-11-29 Novel Drug Solutions Llc Pharmaceutical compositions for intraocular administration and methods for fabricating thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220062303A1 (en) * 2020-08-26 2022-03-03 Somerset Therapeutics, Llc Prednisolone and moxifloxacin compositions and methods
US11298315B2 (en) * 2020-08-26 2022-04-12 Somerset Therapeutics, Llc. Triamcinolone and moxifloxacin compositions
US20230137582A1 (en) * 2021-08-26 2023-05-04 Somerset Therapeutics, Llc Quinolone dispersions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057866A2 (en) * 1999-03-31 2000-10-05 Insite Vision Incorporated Use of azalide antibiotics for the topical treatment or prevention of ocular infections
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20100222308A1 (en) * 2007-06-06 2010-09-02 Shenzhen Regoo Laboratories Co., Ltd. Ophthalmic, otic or nasal pharmaceutical composition and the use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003248033B2 (en) * 1998-09-30 2007-01-18 Alcon Laboratories, Inc. Antibiotic Compositions for Treatment of the Eye, Ear and Nose
US8372814B2 (en) * 2004-06-07 2013-02-12 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
AU2008329876A1 (en) * 2007-11-27 2009-06-04 Alcon Research, Ltd. Topical ophthalmic or otic solution formulations containing moxifloxacin hydrochloride and dexamethasone phosphate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057866A2 (en) * 1999-03-31 2000-10-05 Insite Vision Incorporated Use of azalide antibiotics for the topical treatment or prevention of ocular infections
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20100222308A1 (en) * 2007-06-06 2010-09-02 Shenzhen Regoo Laboratories Co., Ltd. Ophthalmic, otic or nasal pharmaceutical composition and the use thereof

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10993908B2 (en) 2012-05-03 2021-05-04 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11642317B2 (en) 2012-05-03 2023-05-09 The Johns Hopkins University Nanocrystals, compositions, and methods that aid particle transport in mucus
US10945948B2 (en) 2012-05-03 2021-03-16 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9393212B2 (en) 2012-05-03 2016-07-19 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US9393213B2 (en) 2012-05-03 2016-07-19 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US9532955B2 (en) 2012-05-03 2017-01-03 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US10857096B2 (en) 2012-05-03 2020-12-08 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9737491B2 (en) 2012-05-03 2017-08-22 The Johns Hopkins University Nanocrystals, compositions, and methods that aid particle transport in mucus
US11878072B2 (en) 2012-05-03 2024-01-23 Alcon Inc. Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11219597B2 (en) 2012-05-03 2022-01-11 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US10688045B2 (en) 2012-05-03 2020-06-23 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US10736854B2 (en) 2012-05-03 2020-08-11 The Johns Hopkins University Nanocrystals, compositions, and methods that aid particle transport in mucus
US10688041B2 (en) 2012-05-03 2020-06-23 Kala Pharmaceuticals, Inc. Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus
US10646436B2 (en) 2012-05-03 2020-05-12 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US10646437B2 (en) 2012-05-03 2020-05-12 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11872318B2 (en) 2012-05-03 2024-01-16 The Johns Hopkins University Nanocrystals, compositions, and methods that aid particle transport in mucus
US11219596B2 (en) 2012-05-03 2022-01-11 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11318088B2 (en) 2012-05-03 2022-05-03 Kala Pharmaceuticals, Inc. Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus
US10398703B2 (en) 2013-02-15 2019-09-03 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9877970B2 (en) 2013-02-15 2018-01-30 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9827248B2 (en) 2013-02-15 2017-11-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10966987B2 (en) 2013-02-15 2021-04-06 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US11369611B2 (en) 2013-02-20 2022-06-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10285991B2 (en) 2013-02-20 2019-05-14 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10758539B2 (en) 2013-02-20 2020-09-01 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9861634B2 (en) 2013-02-20 2018-01-09 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9833453B2 (en) 2013-02-20 2017-12-05 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US11510916B2 (en) 2013-07-22 2022-11-29 Novel Drug Solutions Llc Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US11684570B2 (en) 2013-07-22 2023-06-27 Novel Drug Soultions Llc Pharmaceutical ophthalmic compositions
US11439590B2 (en) 2013-07-22 2022-09-13 Novel Drug Solutions Llc Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US10160765B2 (en) 2013-11-01 2018-12-25 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9790232B2 (en) 2013-11-01 2017-10-17 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10975090B2 (en) 2013-11-01 2021-04-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US11713323B2 (en) 2013-11-01 2023-08-01 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10618906B2 (en) 2013-11-01 2020-04-14 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10766907B2 (en) 2016-09-08 2020-09-08 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10626121B2 (en) 2016-09-08 2020-04-21 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US11104685B2 (en) 2016-09-08 2021-08-31 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US11021487B2 (en) 2016-09-08 2021-06-01 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof

Also Published As

Publication number Publication date
WO2013065029A1 (en) 2013-05-10

Similar Documents

Publication Publication Date Title
WO2013065028A1 (en) Fixed dose combination containing azithromycin and loteprednol for treatment of ocular infections
CN103417472B (en) For treating the control release corticosteroid composition and method of otic conditions
JP7362870B2 (en) Pharmaceutical composition for intraocular administration containing an antibacterial agent and an anti-inflammatory agent
US11510916B2 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
CA2840626A1 (en) Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
US20230277452A1 (en) Compositions, devices and methods for treating nasal, otic and other tissue infection and/or inflammation
US20160184323A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20190105320A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
JP2023058566A (en) Stable peptide composition
US11446242B2 (en) Suspension component-specific triamcinolone and moxifloxacin compositions and associated methods of use
US11382910B2 (en) Loteprednol and moxifloxacin compositions and methods
JP2022516099A (en) Ophthalmic pharmaceutical composition and treatment method for cancer surface diseases
CN1750828A (en) Use of steroids to treat persons suffering from ocular disorders
US11484538B2 (en) Bromfenac, prednisolone, and moxifloxacin compositions and methods
RU2812900C2 (en) Anesthetic composition and method of eye anesthetization
US20240050446A1 (en) Dexamethasone for treatment of blepharitis
US20170007635A1 (en) Ocular treatment with reduced intraocular pressure
CA3188400A1 (en) Thermo-sensitive permeation enhancing formulations for drug delivery
US20230137582A1 (en) Quinolone dispersions
US20160045432A1 (en) Intraocular lens comprising pharmaceutical compositions and methods for fabricating thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12798864

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12798864

Country of ref document: EP

Kind code of ref document: A1